Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,602 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
荣昌生物制药（烟台）股份有限公司关于参加“对话成长”2025年度暨2026年一季度集体业绩说明会的公告
Regulatory Filings
2026-05-06 Chinese
DATE OF BOARD MEETING
Report Publication Announcement Classification · 85% confidence The document is a short notice announcing the date of a Board meeting to consider and approve the company’s first quarterly results and their publication. It does not contain the results themselves or any management changes. This fits the definition of a Report Publication Announcement (RPA), which is used for announcements regarding the timing or publication of company reports.
2026-04-16 English
VOLUNTARY ANNOUNCEMENT - Receipt of US$650 Million Upfront Payment from AbbVie under the Exclusive License Agreement for RC148
Regulatory Filings Classification · 82% confidence The document is a voluntary announcement by RemeGen Co., Ltd. disclosing the receipt of a $650 million upfront payment under an exclusive license agreement with AbbVie. It is not an annual or interim report, earnings release, board change, M&A notice, dividend notice, or share capital transaction. It is a business update that does not fit any specific category (e.g., not fundraising debt or equity, not governance, not legal). Therefore, it falls into the fallback category of a general regulatory announcement (Regulatory Filings).
2026-04-15 English
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 85% confidence The document is an FF301 Monthly Return form under the HKEX Listing Rules summarising movements in authorised/issued share capital and public float sufficiency for the month ended 31 March 2026. It is a routine monthly regulatory filing to the stock exchange rather than a standalone annual/interim report, earnings release, dividend notice, or a specific transaction announcement. It does not announce a new financing event, board change, or M&A activity, nor is it a call transcript or presentation. Therefore, it falls under the general "Regulatory Filings" category.
2026-04-14 English
VOLUNTARY ANNOUNCEMENT - Approval of the New Drug Application for Disitamab Vedotin for the Indication of HER2-Expressing Urothelial Carcinoma
Regulatory Filings Classification · 82% confidence The document is a voluntary announcement on HKEX by RemeGen Co., Ltd. regarding the approval of a new drug indication by the Chinese regulatory body. It contains no financial statements or voting results, no management change, no share transactions, and it is not an earnings release or an investor presentation. It is a material regulatory announcement about product approval, which does not map to any more specific category, so it falls under the fallback category of general regulatory filings (RNS).
2026-04-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 85% confidence The document is an HKEX ‘Monthly Return for Equity Issuer and Hong Kong Depositary Receipts’ (Form FF301) covering share capital movements, issued and treasury shares, and public float confirmation for the month ended 31 March 2026. It is a routine compliance return under Chapter 19B of the Listing Rules, not a financial report (10-K/IR), earnings release, investor presentation, management change, or specific share issue announcement. This fits the generic category of a regulatory filing. Therefore, it should be classified as RNS.
2026-04-09 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.